HTA4 Pembrolizumab Vs. Standard of Care Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with High Pd-L1 Expression Levels: A Cost-Utility Analysis from the Ontario, Canada Public Payer Perspective
Chu, R., Tudor, R., Choi, D.S., Wong, O., Chan, KKW, Leighl, N.B., Chan, BCF, Coyte, P.C., Rebecca, H.H.
Published in Value in health (01.06.2023)
Published in Value in health (01.06.2023)
Get full text
Journal Article
Cost-Utility Analysis: Understanding The Economic Impact Of Surgical Non-Response In Orthopaedic HIP, Knee And Spine Surgery For Osteoarthritis
Rampersaud, Y.R., Perruccio, A.V., Collett, E., Sundararajan, K., Montoya, L., Power, J.D., Canizares, M., Davey, J.R., Gandhi, R., Syed, K.A., Veillette, C.J., Coyte, P.C., Mahomed, N.N.
Published in Osteoarthritis and cartilage (01.03.2023)
Published in Osteoarthritis and cartilage (01.03.2023)
Get full text
Journal Article
Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada
Ramsay, L.C., Anyiwe, K., Li, M., Macdonald, L., Coyte, P.C., Sander, B.
Published in Vaccine (07.03.2019)
Published in Vaccine (07.03.2019)
Get full text
Journal Article
A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer
Parmar, A, Richardson, M, Coyte, P C, Cheng, S, Sander, B, Chan, K K W
Published in Current oncology (Toronto) (01.08.2020)
Published in Current oncology (Toronto) (01.08.2020)
Get full text
Journal Article